Andra AP fonden Has $99.88 Million Holdings in Astrazeneca Plc $AZN

Andra AP fonden increased its position in shares of Astrazeneca Plc (NYSE:AZN) by 122.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 526,714 shares of the company’s stock after purchasing an additional 290,412 shares during the quarter. Astrazeneca accounts for approximately 1.1% of Andra AP fonden’s investment portfolio, making the stock its 15th largest position. Andra AP fonden’s holdings in Astrazeneca were worth $99,876,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Professional Advisory Services Inc. acquired a new stake in shares of Astrazeneca in the second quarter valued at about $30,241,000. Wealthcare Advisory Partners LLC acquired a new position in shares of Astrazeneca in the second quarter worth approximately $2,296,000. Westport Asset Management Inc. bought a new stake in Astrazeneca in the second quarter valued at approximately $1,422,000. Madison Asset Management LLC acquired a new stake in Astrazeneca during the 2nd quarter valued at approximately $4,041,000. Finally, Plato Investment Management Ltd acquired a new stake in Astrazeneca during the 2nd quarter valued at approximately $5,901,000. 20.35% of the stock is owned by institutional investors.

Astrazeneca Trading Up 0.2%

Shares of NYSE:AZN traded up $0.33 during mid-day trading on Tuesday, hitting $168.43. The company had a trading volume of 1,060,194 shares, compared to its average volume of 2,806,251. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.89 and a quick ratio of 0.67. Astrazeneca Plc has a one year low of $145.79 and a one year high of $212.71. The firm has a fifty day moving average price of $164.03 and a 200 day moving average price of $180.13. The company has a market capitalization of $261.22 billion, a PE ratio of 25.19, a price-to-earnings-growth ratio of 1.41 and a beta of 0.25.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Monday, July 27th. The company reported $2.63 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.13. Astrazeneca had a net margin of 17.02% and a return on equity of 31.45%. The business had revenue of $15.38 billion during the quarter, compared to analysts’ expectations of $15.44 billion. During the same period last year, the company posted $2.17 earnings per share. The business’s quarterly revenue was up 6.4% on a year-over-year basis. As a group, research analysts forecast that Astrazeneca Plc will post 9.34 EPS for the current year.

Astrazeneca News Roundup

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Enhertu gains important reimbursement support in England. The NHS cleared AstraZeneca and Daiichi Sankyo’s Enhertu for patients with HER2-low metastatic breast cancer, reversing an earlier cost-effectiveness-related rejection. Expanded NHS access could increase the drug’s eligible patient population and strengthen its commercial outlook. AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England
• Positive Sentiment: European regulatory momentum broadens AstraZeneca’s pipeline. The European Medicines Agency’s CHMP issued positive opinions for Enhertu and Klygefa. Klygefa was recommended for AChR-positive generalized myasthenia gravis based on Phase III results and offers a once-weekly treatment option. CHMP opinions are not final approvals, but they generally support the products’ path to commercialization in Europe. AstraZeneca’s Enhertu, Klygefa Get Positive CHMP Opinions in EU
• Positive Sentiment: Efzimfotase alfa received FDA priority review. The designation for the hypophosphatasia treatment may accelerate the U.S. regulatory process and highlights another potential growth driver beyond AstraZeneca’s established oncology portfolio. FDA Grants Priority Review to AstraZeneca’s Efzimfotase Alfa
• Positive Sentiment: Erste Group Bank raised its earnings forecasts. The bank increased its FY2026 EPS estimate to $10.34 from $10.17 and its FY2027 estimate to $11.50 from $11.44. Both forecasts are above the cited full-year consensus estimate of $9.34, suggesting confidence in AstraZeneca’s earnings trajectory.
• Neutral Sentiment: Market-performance comparisons remain mixed. Recent coverage noted that AZN shares advanced but continued to lag the broader market, keeping valuation, execution, patent exposure and pipeline delivery as important investor concerns. AstraZeneca Ascends But Remains Behind Market

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a research report on Friday, June 26th. Wall Street Zen cut shares of Astrazeneca from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Zacks Research lowered shares of Astrazeneca from a “hold” rating to a “strong sell” rating in a report on Monday, September 14th. CICC Research began coverage on shares of Astrazeneca in a research report on Sunday, August 23rd. They set an “outperform” rating and a $198.00 price target on the stock. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of Astrazeneca in a report on Wednesday, July 1st. Fourteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Astrazeneca presently has an average rating of “Moderate Buy” and an average target price of $206.67.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company focused on the discovery, development and commercialization of prescription medicines. Its principal therapeutic areas include oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology conditions, and rare diseases.

The company’s portfolio includes medicines such as Tagrisso, Imfinzi and Lynparza for cancer; Farxiga for cardiovascular, kidney and metabolic conditions; Fasenra for severe asthma; and Symbicort for respiratory disease.